Valuation: Capricor Therapeutics, Inc.

Market Cap 1.14B 1B 932M 855M 1.61B 110B 1.63B 11.07B 4.32B 54.01B 4.28B 4.19B 187B P/E 2026 *
-33.3x
P/E 2027 * -30.1x
Enterprise Value 1.14B 1B 932M 855M 1.61B 110B 1.63B 11.07B 4.32B 54.01B 4.28B 4.19B 187B EV / Sales 2026 *
9.66x
EV / Sales 2027 * 9.33x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day-0.66%
1 week+1.34%
Current month-18.19%
1 month-35.20%
3 months-44.15%
6 months-15.09%
Current year-31.74%
1 week 18.3
Extreme 18.305
20.54
1 month 18.3
Extreme 18.305
27.05
Current year 18.3
Extreme 18.305
36.82
1 year 4.3
Extreme 4.3
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 19/11/2013
Director of Finance/CFO 40 31/12/2017
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Chairman 70 31/10/2013
Director/Board Member 68 19/11/2013
Director/Board Member 79 19/11/2013
Date Insider Type Main position Quantity % Market Cap.
25/06/26 Fiscal year

Chief Financial Officer

72,300 0.1248%
25/06/26 Fiscal year

General Counsel

72,300 0.1248%
24/06/26 Fiscal year

General Counsel

1,200 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+1.34%+179.04%+343.69% 1.14B
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.00%+1.28%+54.07%+184.84% 24.12B
Weighted average by Cap. -0.87%+2.09%+40.36%+134.49%

Financials

2026 *2027 *
Net sales 118M 104M 96.45M 88.5M 166M 11.37B 169M 1.15B 447M 5.59B 443M 434M 19.33B 122M 107M 99.92M 91.69M 172M 11.78B 175M 1.19B 464M 5.79B 459M 449M 20.03B
Net income -28.4M -24.95M -23.2M -21.29M -40M -2.74B -40.62M -275M -108M -1.34B -107M -104M -4.65B -48.17M -42.31M -39.34M -36.1M -67.83M -4.64B -68.88M -467M -183M -2.28B -181M -177M -7.88B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
24/07/26 US$19.70 -0.66% 2,469,814
23/07/26 US$19.83 +4.87% 2,009,540
22/07/26 US$18.91 -4.45% 1,545,003
21/07/26 US$19.79 +1.49% 2,257,379
20/07/26 US$19.50 +0.31% 1,911,621
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.70USD
Average target price
53.60USD
Spread / Average Target
+172.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock